60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals develops medicines to prevent and treat infectious diseases. Its main product helps travelers and military personnel avoid malaria. The company also researches new uses for its drugs against viruses and other infections.

What’s in the Medicine Cabinet?

• Malaria Prevention (Arakoda): FDA-approved pill for malaria prevention, mainly for travelers and military; 99% of product revenue in Q2 2025.
• COVID-19 Therapy (Tafenoquine): In clinical trials for treating COVID-19; targets patients at risk of severe illness.
• Fungal and Tick-Borne Disease Research: Developing treatments for fungal lung infections, tick-borne diseases, and candidiasis (a common yeast infection).
• Dengue and Respiratory Virus Program (Celgosivir): Early-stage research for dengue fever and respiratory viruses.
• Research Contracts: Provides clinical trial supplies and services, including work with the U.S. Army and universities.

Growth Spurts and Global Moves

• Launched Arakoda in the U.S. (2019), Australia (as Kodatef), and Europe (2022).
• Formed exclusive distribution partnerships with Biocelect (Australia) and Scandinavian Biopharma (Europe).
• Secured U.S. Army license for tafenoquine (2015) and patent license with Tufts Medical Center (2024).
• Expanded product line with new Arakoda 8-count bottle in June 2025.
• Raised approximately $4.46 million in net proceeds from the July 2025 public offering.

Why 60 Degrees Stands Out (Without the Fever)

The company focuses on infectious disease prevention, with a single FDA-approved product and a pipeline of new uses. Its global reach is supported by exclusive distribution deals in Australia and Europe. Strategic research contracts and licensing agreements help diversify revenue and expand its market presence.

Five Things You Need to Know

• Net revenue was $257,820 in Q2 2025, up 614% year-over-year.
• Gross margin improved to 50.4% in Q2 2025, from 28.3% in Q2 2024.
• Operating loss was $(1,604,828) in Q2 2025, improving 61.7% from Q2 2024.
• Cash and equivalents were $2.0 million at June 30, 2025, before July’s $4.46 million raise.

Bottom Line

60 Degrees Pharmaceuticals has evolved from a single-product company to one with a growing research pipeline and global partnerships. Its focus on infectious diseases and strategic alliances shape its current business model.